Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 11 April 2025, including: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
- Trump’s Tariff Rollercoaster Keeps Pharma On Edge
- Regulatory And Macroeconomic Uncertainty Hang Over Q1 Earnings Season
- Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings
- China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition
- AZ’s Oncology R&D Head On China’s Scientific Promise And True Innovation
